Hologic ($HOLX) is planning to close down its Breast Biopsy Solutions facility in Indianapolis, laying off 141 employees in the process.
In a letter to the state's Department of Workforce Development, posted by Inside Indiana Business, the company says it will cut staff in phases from March to June and shut down the site afterward.
Hologic operates two other breast imaging facilities in Connecticut and Delaware, but it's unclear whether the company plans to port its biopsy business elsewhere or exit that market entirely. Hologic didn't respond to requests for comment Friday.
The company, which specializes in women's health, has been shuffling its business model since it closed a $3.8 billion buyout of Gen-Probe last year, selling off its Lifecodes transplant diagnostics unit for $85 million earlier this month and tightening its focus on STI assays and women's-health-related diagnostics and devices.
Hologic took a $77.8 million loss in the last quarter--which it mostly attributed to costs related to the Gen-Probe buyout--but the company is expecting big things in 2013, as integrating its new acquisition will significantly increase its diagnostics presence.
- here's Inside Indiana Business' report
- read Hologic's letter (pdf)